You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
石藥集團(01093.HK):“TG103注射液”用於治療非酒精性脂肪性肝炎獲臨牀試驗批准
格隆匯 09-09 17:12

格隆匯9月9日丨石藥集團(01093.HK)發佈公吿,集團1類生物製品創新藥“TG103注射液”已獲中國國家藥品監督管理局批准,可在中國開展用於治療非酒精性脂肪性肝炎(NASH)的臨牀試驗。

根據披露,TG103注射液是創新型長效重組人源胰高血糖素樣肽-1(GLP-1)Fc融合蛋白,為胰高血糖素樣肽-1受體激動劑(glucagon-like peptide-1 receptor agonist,GLP-1 RA)。研究發現GLP-1 RA對改善肝脂肪變性和炎症以及逆轉肝纖維化方面具有顯著療效,且TG103注射液臨牀前研究顯示可顯著改善NASH相關症狀和病理結果,因此TG103注射液在NASH的治療上具有重大的臨牀價值。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account